Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av deltakere med revmatoid artritt (FLEX V)

11. mai 2018 oppdatert av: Eli Lilly and Company

En fase 3, multisenter, randomisert, dobbeltblind, placebokontrollert studie for å evaluere effektiviteten og sikkerheten til LY2127399 hos pasienter med moderat til alvorlig revmatoid artritt (RA) som hadde en utilstrekkelig respons på en eller flere TNF-α-hemmere (FLEX) V)

Hovedformålet med denne studien er å hjelpe til med å svare på om LY2127399 er trygt og effektivt i behandlingen av revmatoid artritt hos deltakere med utilstrekkelig respons på en eller flere tumornekrosefaktor-alfa (TNF-α)-hemmere.

Denne studien består av 2 perioder:

Periode 1: 24 ukers blindbehandling

Periode 2: 48 ukers oppfølging etter behandling

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

456

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Buenos Aires, Argentina, C1280AEB
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Córdoba, Argentina, X5016KEH
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Lujan, Argentina, 6700
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Mar Del Plata, Argentina, B7600FZN
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Quilmes, Argentina, B1878DVC
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • San Isidro, Argentina, B1642AKG
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tucuman, Argentina, 4000
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Malvern East, Australia, 3145
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • New South Wales
      • Kogarah, New South Wales, Australia, 04266-010
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Queensland
      • Herston, Queensland, Australia, 4029
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Campinas, Brasil, 13059-000
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Goiania, Brasil, 74110-120
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Juiz De Fora, Brasil, 36010-570
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • São Paulo, Brasil, 04266-010
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bogota, Colombia
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Medellin, Colombia
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Kazan, Den russiske føderasjonen, 420029
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Khanty-Mansiysk, Den russiske føderasjonen, 628012
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Kursk, Den russiske føderasjonen, 305007
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Moscow, Den russiske føderasjonen, 115093
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Nizhny Novgorod, Den russiske føderasjonen, 603005
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Petrozavodsk, Den russiske føderasjonen, 185019
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Saint Petersburg, Den russiske føderasjonen, 191104
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Stavropol, Den russiske føderasjonen, 355017
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Voronezh, Den russiske føderasjonen, 394066
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Alabama
      • Birmingham, Alabama, Forente stater, 35216
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Huntsville, Alabama, Forente stater, 35810
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Arizona
      • Paradise Valley, Arizona, Forente stater, 85253
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Phoenix, Arizona, Forente stater, 85018
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Scottsdale, Arizona, Forente stater, 85251
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Arkansas
      • Jonesboro, Arkansas, Forente stater, 72401
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Little Rock, Arkansas, Forente stater, 72205
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • California
      • Escondido, California, Forente stater, 92027
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Fresno, California, Forente stater, 93720
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Hemet, California, Forente stater, 92543
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Huntington Beach, California, Forente stater, 92646
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • La Mesa, California, Forente stater, 91942
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Loma Linda, California, Forente stater, 92354
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Long Beach, California, Forente stater, 90808
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Los Angeles, California, Forente stater, 90022
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • San Diego, California, Forente stater, 92108
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Santa Monica, California, Forente stater, 90404
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Torrance, California, Forente stater, 90505
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tustin, California, Forente stater, 92780
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Upland, California, Forente stater, 91786
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Whittier, California, Forente stater, 90606
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Wildomar, California, Forente stater, 92595
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Colorado
      • Colorado Springs, Colorado, Forente stater, 80910
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Denver, Colorado, Forente stater, 80209
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Delaware
      • Lewes, Delaware, Forente stater, 19958
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Florida
      • Aventura, Florida, Forente stater, 33180
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Boca Raton, Florida, Forente stater, 33486
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Boynton Beach, Florida, Forente stater, 33472
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • DeBary, Florida, Forente stater, 32713
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Miami, Florida, Forente stater, 33173
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • New Port Richey, Florida, Forente stater, 34652
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Palm Harbor, Florida, Forente stater, 34684
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Pinellas Park, Florida, Forente stater, 33781
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tamarac, Florida, Forente stater, 33321
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tampa, Florida, Forente stater, 33609
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Venice, Florida, Forente stater, 34292
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Vero Beach, Florida, Forente stater, 32960
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • West Palm Beach, Florida, Forente stater, 33401
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Georgia
      • Atlanta, Georgia, Forente stater, 30342
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Decatur, Georgia, Forente stater, 30033
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Dunwoody, Georgia, Forente stater, 30338
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Gainesville, Georgia, Forente stater, 30501
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Marietta, Georgia, Forente stater, 30060
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Stockbridge, Georgia, Forente stater, 30281
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Idaho
      • Eagle, Idaho, Forente stater, 83616
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Idaho Falls, Idaho, Forente stater, 83404
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Illinois
      • Peoria, Illinois, Forente stater, 61636
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Rock Island, Illinois, Forente stater, 61201
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Indiana
      • Brownsburg, Indiana, Forente stater, 46112
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Evansville, Indiana, Forente stater, 47714
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Indianapolis, Indiana, Forente stater, 46227
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Kentucky
      • Bowling Green, Kentucky, Forente stater, 42101
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Lexington, Kentucky, Forente stater, 40504
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Owensboro, Kentucky, Forente stater, 42303
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Louisiana
      • Monroe, Louisiana, Forente stater, 71203
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Maryland
      • Wheaton, Maryland, Forente stater, 20902
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Massachusetts
      • Haverhill, Massachusetts, Forente stater, 01830
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Worcester, Massachusetts, Forente stater, 01605
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Michigan
      • Saint Clair Shores, Michigan, Forente stater, 48081
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Minnesota
      • Edina, Minnesota, Forente stater, 55435
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Mississippi
      • Flowood, Mississippi, Forente stater, 39232
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Jackson, Mississippi, Forente stater, 39202
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Missouri
      • Cape Girardeau, Missouri, Forente stater, 63703
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Florissant, Missouri, Forente stater, 63031
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Saint Louis, Missouri, Forente stater, 63131
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Montana
      • Kalispell, Montana, Forente stater, 59901
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89128
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • New Hampshire
      • Nashua, New Hampshire, Forente stater, 03060
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • New Jersey
      • Berkeley Heights, New Jersey, Forente stater, 07922
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Clifton, New Jersey, Forente stater, 07012
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87108
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • New York
      • Brooklyn, New York, Forente stater, 11201
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28210
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Greensboro, North Carolina, Forente stater, 27408
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Hickory, North Carolina, Forente stater, 28601
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Sanford, North Carolina, Forente stater, 27330
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • North Dakota
      • Bismarck, North Dakota, Forente stater, 58502
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45242
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Cleveland, Ohio, Forente stater, 44109
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tulsa, Oklahoma, Forente stater, 74104
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Pennsylvania
      • Bethlehem, Pennsylvania, Forente stater, 18017
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Erie, Pennsylvania, Forente stater, 16508
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Limerick, Pennsylvania, Forente stater, 19468
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Wexford, Pennsylvania, Forente stater, 15090
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • South Carolina
      • Columbia, South Carolina, Forente stater, 29204
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Greenville, South Carolina, Forente stater, 29601
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Greer, South Carolina, Forente stater, 29651
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Myrtle Beach, South Carolina, Forente stater, 29572
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Taylors, South Carolina, Forente stater, 29687
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Tennessee
      • Knoxville, Tennessee, Forente stater, 37909
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Memphis, Tennessee, Forente stater, 38119
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Nashville, Tennessee, Forente stater, 37205
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Texas
      • Austin, Texas, Forente stater, 78731
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Houston, Texas, Forente stater, 77008
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Lubbock, Texas, Forente stater, 79424
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Mesquite, Texas, Forente stater, 75150
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • San Antonio, Texas, Forente stater, 78217
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Sugar Land, Texas, Forente stater, 77478
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Vermont
      • Burlington, Vermont, Forente stater, 05401
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Virginia
      • Chesapeake, Virginia, Forente stater, 23320
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Danville, Virginia, Forente stater, 24541
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Richmond, Virginia, Forente stater, 23225
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Washington
      • Spokane, Washington, Forente stater, 99204
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tacoma, Washington, Forente stater, 98405
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Wenatchee, Washington, Forente stater, 98801
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • West Virginia
      • Clarksburg, West Virginia, Forente stater, 26301
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Racine, Wisconsin, Forente stater, 53406
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Montpellier, Frankrike, 34295
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Nice, Frankrike, 06202
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Orleans, Frankrike, 45000
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Paris, Frankrike, 75018
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Saint-Etienne Cedex 02, Frankrike, 42055
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Strasbourg, Frankrike, 67 098
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Toulouse, Frankrike, 31059
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Haidari/Athens, Hellas, 12462
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Heraklion, Hellas, 71110
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Larissa, Hellas, 411 10
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Thessaloniki, Hellas, 54642
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Arenzano, Italia, 16011
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Fukuoka, Japan, 807-8555
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Gunma, Japan, 370-0053
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Hyogo, Japan, 673-1462
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Kanagawa, Japan, 216-8511
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Miyazaki, Japan, 880-0122
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Nagasaki, Japan, 852-8501
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Okayama, Japan, 700-8558
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tokyo, Japan, 162
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Incheon, Korea, Republikken, 400-711
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Seoul, Korea, Republikken, 150-713
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Suwon-City, Korea, Republikken, 442-721
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Perak, Malaysia, 30990
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Putrajaya, Malaysia, 62250
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Sarawak, Malaysia, 93586
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Chihuahua, Mexico, 31000
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Col Centro, Mexico, 80000
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Guadalajara, Mexico, 44620
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Mexico City, Mexico, 03720
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Monterrey, Mexico, 64000
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Queretaro, Mexico, 76000
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • San Luis Potosi, Mexico, 78200
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tlalpan, Mexico, 14080
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Hamilton, New Zealand, 3204
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Rotorua, New Zealand, 3010
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tauranga, New Zealand, 3140
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Timaru, New Zealand
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bydgoszcz, Polen, 85-168
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Elblag, Polen, 82-300
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Lublin, Polen, 20-607
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Plock, Polen, 09-400
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Torun, Polen, 87-100
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Warsaw, Polen, 02-118
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Barcelona, Spania, 08034
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bilboa, Spania, 48013
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • La Coruña, Spania, 15006
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Madrid, Spania, 28046
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Manises, Spania, 46940
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Santiago De Compostela, Spania, 15706
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Benoni, Sør-Afrika, 1500
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bloemfontein, Sør-Afrika, 9301
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Limpopo, Sør-Afrika, 0380
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Keelung, Taiwan, 204
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Taichung, Taiwan, 40705
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Taipei, Taiwan, 112
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bad Doberan, Tyskland, 18209
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bad Nauheim, Tyskland, 61231
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Baden-Baden, Tyskland, 76530
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Berlin, Tyskland, 14059
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Dresden, Tyskland, 01307
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Erlangen, Tyskland, 91054
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Frankfurt, Tyskland, 60590
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Göttingen, Tyskland, 37075
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Koeln, Tyskland, 50924
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Munich, Tyskland, 80639
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inklusjonskriterier:

  • Diagnose av RA på mer enn 6 måneder og mindre enn 15 år
  • Minst 8 ømme og hovne ledd
  • Et unormalt høyt nivå av C-reaktivt protein (CRP) eller erytrocyttsedimentasjonshastighet (ESR)
  • Positiv for revmatoid faktor (RF) eller antisyklisk citrullinert peptid (CCP) antistoff
  • Tidligere behandlet med biologisk TNF-α-hemmerbehandling (infliximab, certolizumab, golimumab, etanercept, adalimumab) og stoppet behandling på grunn av utilstrekkelig effekt eller intoleranse
  • Regelmessig bruk av minst 1 konvensjonelt sykdomsmodifiserende antirevmatisk legemiddel (DMARD), med en stabil dose i minst 8 uker før studiestart
  • Kvinnen må ikke være gravid, ammende eller bli gravid under studien

Ekskluderingskriterier:

  • Bruk av ustabile doser av ikke-steroide antiinflammatoriske legemidler (NSAIDS) de siste 6 ukene
  • Steroidinjeksjon eller intravenøs (IV) infusjon de siste 6 ukene
  • Bruk av mer enn 10 milligram/dag (mg/dag) orale steroider de siste 6 ukene
  • Historie om en alvorlig reaksjon på andre biologiske DMARDs
  • Bruk av en oral kalsineurinhemmer (for eksempel ciklosporin eller takrolimus) de siste 8 ukene
  • Kirurgi på en ledd eller annen større operasjon for mindre enn 2 måneder siden, eller planlegger å ha leddkirurgi eller større operasjon under studien
  • Aktiv fibromyalgi, juvenil kronisk artritt, spondyloartropati, Crohns sykdom, ulcerøs kolitt, psoriasisartritt eller annen systemisk inflammatorisk tilstand unntatt RA
  • Livmorhalskreft eller plateepitelkreft innen de siste 3 årene, eller annen kreft innen de siste 5 årene
  • Mottatt en levende vaksine mottatt i løpet av de siste 12 ukene (for eksempel vaksiner mot meslinger, kusma, røde hunder og vannkopper, og nesespray influensavaksiner)
  • Hepatitt eller humant immunsviktvirus (HIV)
  • En alvorlig bakteriell infeksjon (for eksempel lungebetennelse eller cellulitt) innen 3 måneder eller en alvorlig bein- eller leddinfeksjon innen 6 måneder
  • Symptomer på herpes zoster eller herpes simplex i løpet av den siste måneden
  • Aktiv eller latent tuberkulose (TB)
  • Aktuelle symptomer på en alvorlig lidelse eller sykdom
  • Bruk av et undersøkelsesmiddel i løpet av den siste måneden

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: 120 milligram (mg) LY2127399

Gis hver 4. uke (Q4W) i 24 uker. Deltakerne får en startdose på 240 mg når de starter behandlingen.

I løpet av behandlingsperioden vil deltakerne, for blindende formål, veksle injeksjoner av LY2127399 og injeksjoner med placebo hver 2. uke (Q2W).

Ved uke 16 vil respondere få 1 injeksjon på 120 mg LY2127399 og 1 injeksjon med placebo, etterfulgt av 120 mg LY2127399 Q4W for resten av den 24-ukers behandlingsperioden.

Ved uke 16 vil ikke-respondere (NR) få 1 injeksjon på 90 mg LY2127399 og 1 injeksjon med placebo, etterfulgt av 90 mg LY2127399 Q2W for resten av den 24-ukers behandlingsperioden.

Administreres subkutant (SC)
Administrert SC
Eksperimentell: 90 mg LY2127399

Gitt Q2W i 24 uker. Deltakerne får en startdose på 180 mg når de starter behandlingen.

Ved uke 16 vil både respondere og NR få 1 injeksjon på 90 mg LY2127399 og 1 injeksjon med placebo, etterfulgt av 90 mg LY2127399 Q2W for resten av den 24-ukers behandlingsperioden.

Administreres subkutant (SC)
Placebo komparator: Placebo

Gitt Q2W i 24 uker. Deltakerne får 2 injeksjoner med placebo ved oppstart av behandling.

Ved uke 16 vil respondere få 2 injeksjoner med placebo, etterfulgt av 1 injeksjon med placebo Q2W for resten av den 24-ukers behandlingsperioden.

Ved uke 16 vil NR motta en startdose på 180 mg LY2127399 (2 injeksjoner á 90 mg), etterfulgt av 90 mg LY2127399 Q2W for resten av den 24 uker lange behandlingsperioden.

Administreres subkutant (SC)
Administrert SC

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Prosentandel av deltakere med American College of Rheumatology 20 % (ACR20) svar
Tidsramme: Baseline til og med uke 24
ACR Responder Index: sammensatt av kliniske, laboratorie- og funksjonelle mål for revmatoid artritt (RA). ACR20 Responder: en ≥20 % forbedring fra baseline i både 68 ømme ledd (TJC) og 66 hovne ledd (SJC) og en ≥20 % forbedring i minst 3 av 5 kriterier: deltakerens og legens globale vurdering av sykdomsaktivitet, Health Assessment Questionnaire-Disability Index (HAQ-DI) (som målte deltakernes opplevde vanskelighetsgrad med å utføre daglige aktiviteter), leddsmerter og C-reaktivt protein (CRP). Prosentandel av deltakere som oppnår ACR20-svar = (antall ACR20-svar / antall behandlede deltakere) * 100. Alle NR ved uke 16, så vel som alle deltakere som avbrøt studiebehandlingen når som helst av en eller annen grunn, ble definert som NR fra det tidspunktet og fremover, inkludert uke 24 endepunkt.
Baseline til og med uke 24

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Populasjonsfarmakokinetikk (PK): Konstant clearance
Tidsramme: Baseline til og med uke 24
Populasjonsestimat for konstant clearance som bestemt ved populasjons-PK-analyse. En 2-roms modell ble brukt i PK-modellering. Konstant clearance er PK-parameteren som beskriver den lineære eliminasjonen av LY2127399 fra serum.
Baseline til og med uke 24
Prosentandel av deltakere med American College of Rheumatology 50 % (ACR50) og 70 % (ACR70) svar
Tidsramme: Baseline til og med uke 24
ACR Responder Index: sammensatt av kliniske, laboratoriemessige og funksjonelle mål for RA. ACR50 Responder: hadde en ≥50 % forbedring fra baseline i både 68 TJC og 66 SJC og en ≥50 % forbedring i minst 3 av 5 kriterier: deltakers (Pts) og leges globale vurdering av sykdomsaktivitet, HAQ-DI (målte Pts) ' opplevd vanskelighetsgrad med å utføre daglige aktiviteter), leddsmerter og CRP. Prosentandel av Pt som oppnår ACR50-respons = [antall (antall) ACR50-respondere / antall behandlede Pts]*100. ACR70-responder: hadde en ≥70 % forbedring fra baseline i både TJC og SJC og en ≥70 % forbedring i minst 3 av de samme 5 kriteriene for ACR50. Prosentandel av Pts som oppnår ACR70-respons = (Antall ACR70-respondere / Antall Pts behandlet)*100. Alle NR ved uke 16, så vel som alle Pts som avbrøt studiebehandlingen når som helst av en eller annen grunn, ble definert som NR fra det tidspunktet og fremover, inkludert uke 24 endepunkt.
Baseline til og med uke 24
American College of Rheumatology prosentvis forbedring (ACR-N)
Tidsramme: Baseline til og med uke 24
ACR-N er et kontinuerlig mål på kliniske, laboratoriemessige og funksjonelle utfall ved RA som karakteriserer prosent (%) av forbedring i sykdomsaktivitet fra baseline basert på ACR-kjernesett. Denne indeksen ble beregnet som minimum av enten a) % endring i TJC, b) % endring i SJC, eller c) median % endring av gjenværende 5 ACR-kjernekriterier: Hvis ≥3 komponenter av 5 ACR-kjernekriteriene manglet, så c) ble satt til savnet; hvis noen av 3 komponentene a), b) eller c) manglet, ble ACR-N satt til manglende. Prosentandel av forbedring ble avkortet til området -100 til 100 for å minimere effekten av uteliggere (større verdier indikerer større % forbedring) og negative skårer indikerer en nedgang. Minste kvadraters (LS) gjennomsnitt ble beregnet ved bruk av analyse av kovarians (ANCOVA) med behandling og region som faste faktorer og baseline Disease Activity Score basert på 28 leddtellinger -CRP (DAS28-CRP) som en kovariat.
Baseline til og med uke 24
Endring fra baseline til uke 24 i anbudssammensetning (68 fellestall)
Tidsramme: Baseline, uke 24
Tall for ømme ledd er antall ømme og smertefulle ledd bestemt for hver deltaker ved undersøkelse av 68 ledd. Ledd ble vurdert ved trykk og leddmanipulasjon ved fysisk undersøkelse. Deltakerne ble spurt om smerteopplevelser på disse manipulasjonene og fulgte med på spontane smertereaksjoner. Enhver positiv respons på trykk, bevegelse eller begge deler ble oversatt til en enkelt øm-mot-ikke-tender-dikotomi. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Endre fra baseline til uke 24 i hovne ledd (66 ledd)
Tidsramme: Baseline, uke 24
Antall hovne ledd er antallet hovne ledd bestemt for hver deltaker ved undersøkelse av 66 ledd. Leddene ble klassifisert som enten hovne eller ikke hovne. Hevelse ble definert som palpabel fluktuerende synovitt i leddet. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Endring fra baseline til uke 24 i deltakerens vurdering av smerte [Visual Analog Scale (VAS)]
Tidsramme: Baseline, uke 24
Deltagerens vurdering av deres nåværende leddgiktsmerte ved bruk av VAS varierte fra 0 millimeter (mm) (ingen smerte) til 100 mm (verst mulig smerte). En nedgang i smertescore indikerte en bedring i deltakerens tilstand. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Endring fra baseline til uke 24 i deltakerens globale vurdering av sykdomsaktivitet (VAS)
Tidsramme: Baseline, uke 24
Deltakerens vurdering av deres nåværende leddgiktsykdomsaktivitet ved bruk av VAS varierte fra 0 mm (ingen leddgiktaktivitet) til 100 mm (ekstremt aktiv leddgikt). En reduksjon i sykdomsaktivitetsscore indikerte en bedring i deltakerens tilstand. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Endring fra baseline til uke 24 i Physician's Global Assessment of Disease Activity (VAS)
Tidsramme: Baseline, uke 24
Legens vurdering av deltakerens nåværende artrittsykdomsaktivitet ved bruk av VAS varierte fra 0 mm (ingen leddgiktaktivitet) til 100 mm (ekstremt aktiv leddgikt). En reduksjon i sykdomsaktivitetsscore indikerte en bedring i deltakerens tilstand. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Endring fra baseline til uke 24 i Health Assessment Questionnaire-Disability Index (HAQ-DI)
Tidsramme: Baseline, uke 24
HAQ-DI-spørreskjemaet vurderer deltakerens selvoppfatning av vanskelighetsgrad [0 (uten vanskeligheter), 1 (med noen vanskeligheter), 2 (med store vanskeligheter) og 3 (ikke i stand til å gjøre det)] ved påkledning og stell. , reise seg, spise, gå, hygiene, strekke seg, gripe og utføre andre daglige aktiviteter. Poengsummene for hvert funksjonsområde ble beregnet for å beregne HAQ-DI-score, som varierte fra 0 (ingen funksjonshemming) til 3 (alvorlig funksjonshemming). En nedgang i HAQ-DI-score indikerte en bedring i deltakerens tilstand. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Endring fra baseline til uke 24 i sykdomsaktivitetspoeng basert på 28 leddantall og C-reaktivt proteinnivå (DAS28-CRP)
Tidsramme: Baseline, uke 24
Disease Activity Score (DAS) modifisert til å inkludere 28 leddtellinger (DAS28) besto av sammensatt poengsum av følgende variabler: antall ømme ledd (TJC28), antall hovne ledd (SJC28), CRP (milligram per liter) og deltakerens globale vurdering av sykdom aktivitet ved bruk av VAS (deltaker global VAS). DAS28-CRP=0,56*kvadrat root (sqrt)(TJC28)+0,28*sqrt(SJC28)+0,36*naturlig log(CRP+1)+0,014*deltaker global VAS+0,96. Skårene varierte fra 1,0 til 9,4, der lavere skårer indikerte mindre sykdomsaktivitet og remisjon er DAS28-CRP <2,6. En nedgang i DAS28-CRP indikerte en bedring i deltakerens tilstand. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Prosentandel av deltakere med DAS28-CRP-basert European League Against Rheumatism (EULAR)-respons
Tidsramme: Baseline til og med uke 24
EULAR Responder-indeksen kategoriserer klinisk respons basert på forbedring siden baseline i DAS28-CRP. DAS28-CRP=0,56*sqrt(TJC28)+0,28*sqrt(SJC28)+0,36*naturlig log(CRP+1)+0,014*deltaker global VAS+0,96. DAS28-CRP-score varierer fra 1,0-9,4, der lavere skårer indikerte mindre sykdomsaktivitet. Høy sykdomsaktivitet: DAS28-CRP >5.1, lav sykdomsaktivitet: DAS28-CRP <3.2, og remisjon: DAS28-CRP <2.6. Deltakerne er kategorisert som EULAR-respondere eller NR basert på forbedring av DAS28-CRP-score fra baseline. EULAR DAS28-CRP responder-indeks definerer en god (absolutt: <3,2 eller >1,2 forbedring fra baseline), moderat (absolutt: 3,2-5,1 eller 0,6-1,2 forbedring fra baseline), eller ingen respons (absolutt: >5,1 eller <0,6 forbedring fra baseline). Andel deltakere med DAS28-CRP-basert EULAR-svar = (antall deltakere med spesifikk respons) / (antall deltakere analysert i gruppen) * 100.
Baseline til og med uke 24
Endring fra baseline til uke 24 i medisinske resultater Studie 36-Item Short Form (SF-36) Health Survey Domain and Summary Scores
Tidsramme: Baseline, uke 24
SF-36 er en helserelatert undersøkelse som vurderer deltakerens livskvalitet og består av 36 spørsmål som dekker 8 helsedomener: fysisk funksjon, kroppslig smerte, rollebegrensninger på grunn av fysiske problemer og emosjonelle problemer, generell helse, psykisk helse, sosial funksjon, vitalitet, 2 komponentscore (CS), fysisk CS (PCS) og mental CS (MCS). Domenepoeng beregnes ved å summere hvert element for hvert domene og transformere poengsum til en skala fra 0-100; høyere skårer indikerte bedre helsetilstand. Hvis < 50 % av spørsmålene innenfor et domene ble besvart, ble ikke råskåren beregnet. PCS-score besto av fysisk funksjon, kroppslig smerte, rolle-fysisk og generell helseskala. MCS-score besto av sosial funksjon, vitalitet, mental helse og rolleemosjonelle skalaer. Både PCS og MCS varierer fra 0-100 med høyere poengsum som indikerer bedre mental eller fysisk helse. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling, region som faste faktorer og baseline som kovariat.
Baseline, uke 24
Endring fra baseline til uke 24 i kort tretthetsopptelling (BFI) individuelle elementer og effektpoeng
Tidsramme: Baseline, uke 24
BFI er et kort deltakerrapportert spørreskjema for rask vurdering av alvorlighetsgraden av tretthet og virkningen av tretthet på daglig funksjon de siste 24 timene. BFI inneholder 10 elementer; Det første elementet er imidlertid ikke inkludert i poengsummen på skalaen, da det spørs om vanlig tretthet den siste uken med deltakeren som svarer «ja» eller «nei». De resterende 9 elementene vurderer tretthetsalvorlighet (3 elementer) og innvirkning av tretthet på daglig funksjon (6 elementer) ved å bruke en 11-punkts numerisk skala, med 0 = ingen tretthet og 10 = tretthet så ille som du kan forestille deg. Fatigue impact subscale score er gjennomsnittet av ikke-manglende svar på 6 elementer: generell aktivitet, humør, gangevne, normalt arbeid, relasjoner med andre mennesker og livsglede. Hvis mer enn 3 punkter innenfor tretthetspåvirkningsunderskalaen ikke ble besvart av en deltaker, er underskalaen satt til manglende. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Endring fra baseline til uke 24 i kort form for smerteoversikt (BPI-SF) individuelle elementer og interferensscore
Tidsramme: Baseline, uke 24
BPI-SF er en selvrapportert skala som måler alvorlighetsgraden av smerte basert på den verste smerten, minst smerte, gjennomsnittlig smerte opplevd i løpet av de siste 24 timene og smerte basert på smerten akkurat nå, med skårer fra 0 (ingen smerte ) til 10 (smerte så sterke som du kan forestille deg). Smerteforstyrrelsespoeng er gjennomsnittet av svarene de siste 24 timene til 7 elementer: generell aktivitet, humør, gangevne, normalt arbeid, forhold til andre mennesker, søvn og livsglede [hvert element skåret fra 0 (forstyrrer ikke ) til 10 (komplett forstyrrer)]. Hvis mer enn 3 elementer i Pain Interference Score ikke blir besvart av en deltaker, er poengsummen satt til manglende. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Endring fra baseline til uke 24 i varighet av morgenstivhet (minutter)
Tidsramme: Baseline, uke 24
Etterforskeren spør deltakerne om varigheten av morgenstivheten deres (i minutter) i og rundt leddene og registrerer varigheten. Undersøkeren bør spørre deltakerne om varigheten av morgenstivhet dagen før studiebesøket for å fange opp faktiske symptomer. Hvis morgenstivhetsvarigheten er lengre enn 12 timer (720 minutter), ble den avkortet til 720 minutter for statistiske presentasjoner og analyser. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Tid til ACR20-svar
Tidsramme: Baseline til og med uke 24
Baseline til og med uke 24
Endre fra baseline til uke 24 i absolutt B-celletall
Tidsramme: Baseline, uke 24
Celleoverflatemarkørklyngebetegnelse (CD) 3 negativ, CD20 positiv (CD3-CD20+) definerer totale modne B-celler. B-lymfocyttantigen CD20 er et aktivert-glykosylert fosfoprotein uttrykt på overflaten av alle modne B-celler. Baseline B-celletall er gjennomsnittet av verdiene på eller før datoen for første injeksjon av studiebehandlingen, inkludert ikke-planlagte besøk. En positiv eller negativ endring indikerte henholdsvis en økning eller reduksjon i B-celletall. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Endring fra baseline til uke 24 i serumimmunoglobulin (Ig) nivåer
Tidsramme: Baseline, uke 24
Immunoglobulin (Ig), eller antistoffer, er store proteiner som brukes av immunsystemet for å identifisere og nøytralisere fremmede partikler som bakterier og virus. Deres normale blodnivåer indikerer riktig immunstatus. Endring fra baseline i serumimmunoglobulin A (IgA), immunglobulin G (IgG) og immunglobulin M (IgM) er rapportert. En negativ endring indikerte en reduksjon i Ig-nivåer. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24
Prosentandel av deltakere som utvikler anti-LY2127399 antistoffer
Tidsramme: Baseline til og med uke 24
Deltakere med behandlings-emergent anti-drug antistoff (ADA) var deltakere som hadde en hvilken som helst prøve fra baseline til og gjennom uke 52 som var en 4 ganger økning (2-fortynningsøkning) i immunogenisitetstiter over baseline titer, eller deltakere som testet negativ ved baseline og positiv post-baseline (ved titer på ≥1:20). Andel deltakere med ADA = (antall deltakere med behandlingsutløst ADA) / (antall deltakere vurdert) * 100.
Baseline til og med uke 24
Endre fra baseline til uke 24 i CRP
Tidsramme: Baseline, uke 24
CRP er en indikator på betennelse. En negativ endring indikerte en bedring i deltakerens tilstand. LS-middelverdier ble beregnet ved bruk av ANCOVA med behandling og region som faste faktorer og baseline som en kovariat.
Baseline, uke 24

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. januar 2011

Primær fullføring (Faktiske)

1. mars 2013

Studiet fullført (Faktiske)

1. januar 2014

Datoer for studieregistrering

Først innsendt

14. september 2010

Først innsendt som oppfylte QC-kriteriene

14. september 2010

Først lagt ut (Anslag)

16. september 2010

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

14. mai 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. mai 2018

Sist bekreftet

1. mai 2018

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • 13732
  • H9B-MC-BCDV (Annen identifikator: Eli Lilly and Company)

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere